Abstract: Novel 3,5-dioxo-(2H,4H-triazine derivatives of general formula (I): wherein R.sub.1 is hydrogen, a C.sub.1 -C.sub.4 alkyl radical, phenyl C.sub.1 -C.sub.4 alkyl or phenyl, the phenyl ring being optionally substituted by one or more groupings such as (C.sub.1 -C.sub.3) alkyl, hydroxyl, trifluoromethyl or halogen: R.sub.2 is hydrogen or a (C.sub.1 -C.sub.4) alkyl radical, n can be an integer from 2 to 6; A is a grouping of the aryl piperazino or benzodioxanyl-methylamino or pyridodioxanyl-methylamino type.

Abstract: A 3,5-dioxo-(2H,4H)-1,2,4-triazine compounds of formula I ##STR1## in which: R.sub.1 and R.sub.2, which are identical or different, represent hydrogen or C.sub.1 -C.sub.6 alkyl, n is 2 to 6, inclusive,A represents aryl piperazino II ##STR2## the Ar grouping representing phenyl, naphthyl, pyrimidyl, or pyridyl, unsubstituted or substituted by C.sub.1 -C.sub.3 alkyl, C.sub.1 -C.sub.3 alkoxy, hydroxy, trifluoromethyl, or halogen, or III benzodioxanyl-methyl-amino or pyridodioxanyl-methyl-amino ##STR3## in which R represents hydrogen or C.sub.1 -C.sub.3 alkyl and X represents a nitrogen or carbon atom, therapeutically-acceptable salts and enantiomers thereof, pharmaceutical compositions thereof, and method for treatment of diseases requiring a 5HT.sub.1A receptor agonist therewith.

Abstract: New derivatives of 1,2-dihydro 2-oxo quinoxalines corresponding to the general formula I: ##STR1## in which: R is a hydrogen or halogen atomR.sub.1 is a hydrogen atom or a straight or branched C.sub.1 -C.sub.4 alkyl radicalR.sub.2 is:a hydrogen atoma C(O)R.sub.4 radical in which R.sub.4 is a straight or branched C.sub.1 -C.sub.4 alkyl groupa C(O)NHR.sub.5 radical in which R.sub.5 is a straight or branched C.sub.1 -C.sub.4 alkyl radical or a phenyl groupA is a C.sub.1 -C.sub.4 alkaline chainR.sub.3 represents:a hydrogen atom, a C.sub.1 -C.sub.4 alkyl radical, a C.sub.3 -C.sub.6 cycloalkyl radical, an alcynyl, nitrile, hydroxyl, carboxamido, pyridyl, phenyl group, or a phenyl group substituted by a halogen atom, a C.sub.1 -C.sub.4 alkyl group, a C.sub.1 -C.sub.4 alkoxy group or a nitro groupan alkenyl radical of the formula: ##STR2## in which R.sub.6, R.sub.7 may, independently of each other, be a hydrogen atom, a C.sub.1 -C.sub.

Abstract: Mixed silicates of yttrium and lanthanide and laser using monocrystals of these silicates. The laser has a laser cavity (2) containing as the light emitter a monocrystal (4), means (12,14) for amplifying the light from the monocrystal, means (14) for removing light from the laser cavity and optical pumping means (6), characterized in that the monocrystal is of formula (I):Y.sub.2-2x-2y M.sub.2x Yb.sub.2y SiO.sub.5 (I)in which M represents a lanthanide chosen from among erbium and thulium and x and y represent numbers such that 0<x.ltoreq.0.2 and 0<y.ltoreq.0.2.

Abstract: In the lyophilization of solid, liquid or pasty products the product to be lyophilized is placed in an open secondary container of flexible material which is capable of being subsequently closed and lyophilized in a lyophilization apparatus with the container kept open. On completion of lyophilization the container is closed and the closed container withdrawn from the apparatus. Preferably the container is in the form of a bag, e.g. a heat-sealable plastic bag. A lyophilization apparatus is provided with means for supporting secondary containers accommodating product to be lyophilized, means for keeping the secondary containers open during lyophilization and means for closing the containers on completion of lyophilization.